Hope for brain injury patients: stem cells tested in expanded access trial

NCT ID NCT07164482

AVAILABLE Disease control Sponsor: Hope Biosciences Research Foundation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access study offers stem cell therapy (HB-adMSCs) to up to 8 people with traumatic or non-traumatic brain injury who were not eligible for a related trial. Participants receive 6 intravenous infusions over 16 weeks. The goal is to evaluate safety and whether the treatment can improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells)
What this could lead to: If this works, it could point toward a treatment that helps repair brain damage and improve function after injury.
What could go wrong: This is a very small expanded access study (up to 8 patients) with no control group, so results may not be generalizable. Stem cell treatments carry risks like infusion reactions or unknown long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain injury traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN INJURY

Contacts and locations

Locations

Hope Biosciences Research Foundation
AVAILABLE

Houston, Texas, 77478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.